



CYTOIMMUNE THERAPEUTICS BROADENS SERVICES: A NEW CHAPTER IN DEVELOPMENT AND MANUFACTURING OF CELL THERAPIES

Posted on July 27, 2023



Positioning as a key ally for biotech companies, CytolImmune augments its offerings with autologous and allogeneic T cell and NK cell therapy development and manufacturing services.

Toa Baja, Puerto Rico, July 27, 2023 – CytolImmune Therapeutics is proud to unveil its expanded portfolio, now encompassing cell therapy and manufacturing services. With this latest advancement, clients aiming to pioneer cellular therapeutics will have access to the company's cutting-edge capabilities.

With decades of experience working with T cells and Natural Killer (NK) cells, the team at CytolImmune can modify these cells to express chimeric antigen receptors (CARs), T cell receptors (TCRs), and simultaneously express or secrete bispecific antibodies, cytokines, or other gene products. The result is engineered for an enhanced survival, targeted cytotoxicity, and antibody

dependent cellular cytotoxicity (ADCC), offering innovative solutions for patients in need.

CytoImmune is a key partner for biotechnology companies seeking to advance the field of cell therapy. Biotech companies working with CytoImmune are relieved of the immense burden of establishing their own cGMP manufacturing facilities and bring cell therapy products from discovery into first in human trials.

"We are excited to offer our expertise in cell therapy development and manufacturing to clients working on genetically or virally modified T cell and NK cell technologies," says Jose Eduardo Vidal, Ph.D., Chief Executive Officer of CytoImmune Therapeutics. "Our team is dedicated to advancing the field of cell therapy and helping our partners bring life-changing treatments to patients in need."

Leveraging its state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico, CytoImmune is well-equipped to support the analytical and process development and clinical manufacturing of cutting-edge T cell and NK cell therapies all the way to GMP production. The company's proprietary, robust, and well-characterized NK cell expansion and engineering technologies enable the delivery of high-quality cell therapy solutions to its partners.

This service expansion underscores CytoImmune's dedication to fostering partnerships that fuel the future of cell therapy and improve cancer patients' lives. The company's mastery in cell therapy development and clinical manufacturing will expedite its clients' success and contribute to the growth of the autologous and allogeneic cell therapy industry.

About CytoImmune Therapeutics:

[CytoImmune Therapeutics](#) is at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials. In addition, we are now offering cell therapy development and clinical manufacturing services to both biotechnology companies and academia. Our cutting edge clinical cell manufacturing facility in Toa Baja, Puerto Rico, is custom built to support the development and commercialization of emergent T cell or NK cell therapies. At CytoImmune, we are fostering collaborations that drive the future of cell therapy and improve the lives of cancer patients. For additional information, please visit: [Cytoimmune.com](https://cytoimmune.com)

Media Contact:

Albert Stichka

albert@elkordyglobal.com